Allergan Ligand (ALRI) | Stock Discussion Forums

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical
Allergan Ligand (ALRI)

An SI Board Since August 1997

Posts	SubjectMarks	Bans	Symbol
46	1	0	ALRI

Emcee: Henry Niman	Type: Unmoderated

Introduction Market Data Compact

Allergan Ligand Retinoid Therapeutics, Inc (ALRI) has gained notoriety yesterday due to the HALT of one of its pivotol Phase III trials of topical Panretin, its lead retinoid, for the treatment of Kaposi's Sarcoma. The company is a funding vehicle (has one employee and began with a $100 million bank account) for retinoid research of Allergan (AGN) and Ligand (LGND) who have 50/50 ownership. The shares are callable for $21.97 and ALRI's accellerated spending program should force a call in the next few months.

However, yesterday investors couldn't be contained. After the press release the night before (Aug 26), coupled with several graphics on CNBC, the stock opened at 23 1/2, up 5 3/8, even though it could be called for $21.97. The price quickly came down, but volume continued unabated. Final volume of 469,000 which challenged IBD's NASDAQ Stocks With Greatest % Rise In Volume posting abilities. ALRI was #1 with a % volume change of 9999!

I'll post more info on the relationship between ALRI, AGN, and LGND. However, there is already a good deal of info on the Ligand Breakout! thread.

Go to reply# or date (mm/dd/yy):

Reply	Message Preview	From	Recs	Posted
46	Henry, Will there be a great number of layoffs at ALRI associated w/ this merge	squetch	-	9/27/1997
45	Well, if LGND is covered big time on CNBC today, they shouldn't make the sa	Henry Niman	-	9/25/1997
44	Here's WSJ's interactive edition's version: Ligand and Allergan Exe	Henry Niman	-	9/25/1997
43	Anyone who bought for more than $22 wasn't paying attention. Here's th	Henry Niman	-	9/25/1997
42	I feel bad for those who bought above 22.	squetch	-	9/24/1997
41	songw, Here's more good news for retinoids. The damage that smokers do to	Henry Niman	-	9/17/1997
40	Stan, I just realized that this might help some readers understand the relation	Henry Niman	-	9/17/1997
39	Stan, JNJ actually has a significant diabetes presence through its Lifescan sub	Henry Niman	-	9/10/1997
38	It seems you think WLA is better for diabetes, but a JNJ deal is better for lon	squetch	-	9/9/1997
37	ALRI can be called for $21.97. There are 3.25 million shares outstanding so it	Henry Niman	-	9/9/1997
36	Henry, I think I am making this the remedial LGND thread. You say rumor is >	squetch	-	9/9/1997
35	Thestreet just put out a Ligand story (their top story). They say that LLY is t	Henry Niman	-	9/8/1997
34	stan, Last week buyers opened the price at 23 1/2 which is rediculous since ALR	Henry Niman	-	9/5/1997
33	I feel bad if anybody buys above the call price. Good to see the coverage. I ho	squetch	-	9/5/1997
32	songw,IBD didn't miss it. Check out today's IBD. Big (1/4 page) articl	Henry Niman	-	9/5/1997
31	No we didn't miss it. Have been discussing little else on the LGND thread.	Andrew H	-	9/3/1997
30	songw, See post #16: techstocks.com	Henry Niman	-	9/3/1997
29	Did everyone miss ALRI 50% success rate of "complete and durable remissio	songw	-	9/3/1997
28	Henry, in the midst of the bashing you are taking on a couple of threads, I wan	Andrew H	-	9/2/1997
27	Looks good Henry. I don't understand some of the more complex information,	Larry	-	9/2/1997
26	LGND's "Retinoid Revolution" is a remarkable acheivement from	Henry Niman	-	9/2/1997
25	Just finished reading it there. Seems like good news.	squetch	-	9/2/1997
24	Here's the front end of the LGND review I put up on Biotech Bash: I'll	Henry Niman	-	9/2/1997
23	Stan, Check out Gold Standard Medical services. They give rundowns on new drug	Henry Niman	-	9/1/1997
22	Here's what the WSJ had to say about retinoids when Vesanoid was approv	Henry Niman	-	9/1/1997

Go to reply# or date (mm/dd/yy):